Die Hersteller des Medikaments, die Pharmaunternehmen Eisai (Japan) und Biogen (USA), hatten daraufhin eine zweite Prüfung ...

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis ...

Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking ...

Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.

Biogen posted Q4 adjusted EPS of $3.44, up 17%, beating the $3.35 consensus. Sales rose to $2.46B, surpassing estimates. Biogen forecasts 2025 EPS of $15.25-$16.25, below the $16.34 consensus ...

Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the shares following quarterly results. Though Biogen has ...

Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries ...